Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) insider Lisa Bright sold 394 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $121.33, for a total value of $47,804.02. Following the sale, the insider now owns 23,619 shares in the company, valued at $2,865,693.27. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Lisa Bright also recently made the following trade(s):

  • On Thursday, June 1st, Lisa Bright sold 698 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $110.73, for a total value of $77,289.54.
  • On Thursday, May 25th, Lisa Bright sold 254 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $117.52, for a total value of $29,850.08.
  • On Tuesday, May 16th, Lisa Bright sold 113 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $119.74, for a total value of $13,530.62.
  • On Tuesday, May 2nd, Lisa Bright sold 426 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $114.00, for a total value of $48,564.00.

Intercept Pharmaceuticals, Inc. (ICPT) traded down 0.04% on Friday, hitting $128.45. 209,699 shares of the stock traded hands. The firm’s market cap is $3.21 billion. Intercept Pharmaceuticals, Inc. has a 12-month low of $96.63 and a 12-month high of $177.93. The stock has a 50-day moving average of $119.14 and a 200-day moving average of $115.33.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($4.27) by $0.66. The firm had revenue of $21 million for the quarter, compared to analyst estimates of $15.88 million. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. The business’s revenue for the quarter was up 4566.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($5.17) EPS. Analysts forecast that Intercept Pharmaceuticals, Inc. will post ($14.43) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Insider Selling: Intercept Pharmaceuticals, Inc. (ICPT) Insider Sells 394 Shares of Stock” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/07/16/intercept-pharmaceuticals-inc-icpt-insider-lisa-bright-sells-394-shares-of-stock-updated.html.

A number of large investors have recently made changes to their positions in ICPT. WFG Advisors LP raised its stake in shares of Intercept Pharmaceuticals by 197.1% in the fourth quarter. WFG Advisors LP now owns 2,956 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,961 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares during the last quarter. US Bancorp DE purchased a new stake in Intercept Pharmaceuticals during the first quarter valued at $130,000. Quantbot Technologies LP purchased a new stake in Intercept Pharmaceuticals during the first quarter valued at $170,000. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in Intercept Pharmaceuticals by 39.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,630 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 462 shares during the last quarter. 84.35% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have weighed in on ICPT. Cowen and Company reissued a “buy” rating and issued a $225.00 target price on shares of Intercept Pharmaceuticals in a research note on Monday, April 24th. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 8th. Credit Suisse Group boosted their price target on shares of Intercept Pharmaceuticals from $198.00 to $201.00 and gave the stock an “outperform” rating in a research note on Monday, May 15th. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Finally, Jefferies Group LLC started coverage on shares of Intercept Pharmaceuticals in a research note on Monday, July 10th. They set a “buy” rating and a $275.00 target price for the company. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $195.75.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.